Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor

Fred Hutchinson Cancer Center (FHCC)

Status and phase

Completed

Phase 2

Phase 1

Conditions

Anemia, Aplastic

Treatments

Procedure: Bone marrow transplant

Study type

Interventional

Funder types

Other

Identifiers

NCT00144729

NIH# HL36444-21

IRB# 3632

FHCRC 0800.01

Details and patient eligibility

About

A single arm dose optimization study in which all patients are given a fixed dose of Cytoxan (4 x 50 mg/kg) plus ATG (3 x 30 mg/kg) and the TBI dose starting at 3 x 200 cGy is escalated or de-escalated dependent upon engraftment and toxicity.

Sex

All

Ages

Under 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Life-threatening marrow failure of nonmalignant etiology;
failure to respond to the best available immunosuppressive treatment;
lack of a HLA-identical family member

Exclusion criteria

Severe disease other than aplastic anemia that would severly limit the probability of survival during the graft procedure;
HIV seropositive patients;
clonal abnormalities or myelodysplastic syndrome;